$1.16
3.57% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Immunic, Inc. Stock price

$1.12
+0.12 12.00% 1M
-0.29 20.28% 6M
+0.12 12.00% YTD
-0.27 19.42% 1Y
-10.53 90.39% 3Y
-6.48 85.26% 5Y
-884.88 99.87% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.05 4.27%
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Key metrics

Market capitalization $100.89m
Enterprise Value $42.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.45
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-95.80m
Free Cash Flow (TTM) Free Cash Flow $-76.26m
Cash position $59.07m
EPS (TTM) EPS $-1.24
P/E forward negative
Short interest 4.21%
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Immunic, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Immunic, Inc. forecast:

Buy
100%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
9% 9%
-
-0.12 -0.12
9% 9%
-
- Selling and Administrative Expenses 18 18
17% 17%
-
- Research and Development Expense 78 78
8% 8%
-
-96 -96
4% 4%
-
- Depreciation and Amortization 0.12 0.12
9% 9%
-
EBIT (Operating Income) EBIT -96 -96
4% 4%
-
Net Profit -97 -97
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Positive
Proactive Investors
2 minutes ago
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers.
Positive
Proactive Investors
2 days ago
Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its pro...
Neutral
PRNewsWire
2 days ago
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activation s in Preclinical Models – – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – NEW YORK , Feb. 26, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a c...
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 77
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today